Bioniche Life Sciences announced that it has completed recruitment in its initial Phase 3 registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy – Bacillus Calmette-Guerin (BCG). This FDA Fast Track designated, open-label trial has enrolled 105 patients with non-muscle-invasive bladder cancer in thirty-one urology centers across North America.
Urocidin is a formulation of MCC, a sterile mycobacterial cell wall-DNA complex composition that has a dual mode of action: immune stimulation and direct anticancer activity. Urocidin is administered by trans-urethral catheter directly into the bladder, coming into contact with immune system cells and bladder cancer cells.
For more information call (514) 697-6636 or visit www.bioniche.com.